1
|
Boeckxstaens L, Pauwels E, Vandecaveye V, Deckers W, Cleeren F, Dekervel J, Vandamme T, Serdons K, Koole M, Bormans G, Laenen A, Clement PM, Geboes K, Van Cutsem E, Nackaerts K, Stroobants S, Verslype C, Van Laere K, Deroose CM. Prospective comparison of [ 18F]AlF-NOTA-octreotide PET/MRI to [ 68Ga]Ga-DOTATATE PET/CT in neuroendocrine tumor patients. EJNMMI Res 2023; 13:53. [PMID: 37261615 PMCID: PMC10235004 DOI: 10.1186/s13550-023-01003-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2023] [Accepted: 05/22/2023] [Indexed: 06/02/2023] Open
Abstract
BACKGROUND Fluorine-18-labeled SSAs have the potential to become the next-generation tracer in SSTR-imaging in neuroendocrine tumor (NET) patients given their logistical advantages over the current gold standard gallium-68-labeled SSAs. In particular, [18F]AlF-OC has already shown excellent clinical performance. We demonstrated in our previous report from our prospective multicenter trial that [18F]AlF-OC PET/CT outperforms [68Ga]Ga-DOTA-SSA, but histological confirmation was lacking due to ethical and practical reasons. In this second arm, we therefore aimed to provide evidence that the vast majority of [18F]AlF-OC PET lesions are in fact true NET lesions by analyzing their MR characteristics on simultaneously acquired MRI. We had a special interest in lesions solely detected by [18F]AlF-OC ("incremental lesions"). METHODS Ten patients with a histologically confirmed neuroendocrine tumor (NET) and a standard-of-care [68Ga]Ga-DOTATATE PET/CT, performed within 3 months, were prospectively included. Patients underwent a whole-body PET/MRI (TOF, 3 T, GE Signa), 2 hours after IV injection of 4 MBq/kg [18F]AlF-OC. Positive PET lesions were evaluated for a corresponding lesion on MRI. The diagnostic performance of both PET tracers was evaluated by determining the detection ratio (DR) for each scan and the differential detection ratio (DDR) per patient. RESULTS In total, 195 unique lesions were detected: 167 with [68Ga]Ga-DOTATATE and 193 with [18F]AlF-OC. The DR for [18F]AlF-OC was 99.1% versus 91.4% for [68Ga]Ga-DOTATATE, significant for non-inferiority testing (p = 0.0001). Out of these 193 [18F]AlF-OC lesions, 96.2% were confirmed by MRI to be NET lesions. Thirty-three incremental lesions were identified by [18F]AlF-OC, of which 91% were confirmed by MRI and considered true positives. CONCLUSION The DR of [18F]AlF-OC was numerically higher and non-inferior to the DR of [68Ga]Ga-DOTATATE. [18F]AlF-OC lesions and especially incremental lesions were confirmed as true positives by MRI in more than 90% of lesions. Taken together, these data further validate [18F]AlF-OC as a new alternative for SSTR PET in clinical practice. Trial registration ClinicalTrials.gov: NCT04552847. Registered 17 September 2020, https://beta. CLINICALTRIALS gov/study/NCT04552847.
Collapse
Affiliation(s)
- Lennert Boeckxstaens
- Nuclear Medicine, University Hospitals Leuven and Nuclear Medicine and Molecular Imaging,, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium", Campus Gasthuisberg, Nucleaire Geneeskunde, Herestraat 49, 3000, Leuven, Belgium
| | - Elin Pauwels
- Nuclear Medicine, University Hospitals Leuven and Nuclear Medicine and Molecular Imaging,, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium", Campus Gasthuisberg, Nucleaire Geneeskunde, Herestraat 49, 3000, Leuven, Belgium
| | - Vincent Vandecaveye
- Radiology, Department of Imaging and Pathology, University Hospitals Leuven and Division of Translational MRI, KU Leuven, Leuven, Belgium
| | - Wies Deckers
- Nuclear Medicine, University Hospitals Leuven and Nuclear Medicine and Molecular Imaging,, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium", Campus Gasthuisberg, Nucleaire Geneeskunde, Herestraat 49, 3000, Leuven, Belgium
| | - Frederik Cleeren
- Radiopharmaceutical Research, Department of Pharmacy and Pharmacology, KU Leuven, Leuven, Belgium
| | - Jeroen Dekervel
- Digestive Oncology, University Hospitals Leuven, Leuven, Belgium
| | - Timon Vandamme
- Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Antwerp, Belgium
- Oncology, NETwerk Antwerpen-Waasland CoE, Antwerp, Belgium
| | - Kim Serdons
- Nuclear Medicine, University Hospitals Leuven and Nuclear Medicine and Molecular Imaging,, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium", Campus Gasthuisberg, Nucleaire Geneeskunde, Herestraat 49, 3000, Leuven, Belgium
| | - Michel Koole
- Nuclear Medicine, University Hospitals Leuven and Nuclear Medicine and Molecular Imaging,, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium", Campus Gasthuisberg, Nucleaire Geneeskunde, Herestraat 49, 3000, Leuven, Belgium
| | - Guy Bormans
- Radiopharmaceutical Research, Department of Pharmacy and Pharmacology, KU Leuven, Leuven, Belgium
| | - Annouschka Laenen
- Leuven Biostatistics and Statistical Bioinformatics Center, KU Leuven, Leuven, Belgium
| | - Paul M Clement
- General Medical Oncology, University Hospitals Leuven, Leuven, Belgium
| | - Karen Geboes
- Digestive Oncology, Department of Gastroenterology, Ghent University Hospital, Ghent, Belgium
| | - Eric Van Cutsem
- Digestive Oncology, University Hospitals Leuven, Leuven, Belgium
| | | | - Sigrid Stroobants
- Nuclear Medicine, Faculty of Medicine and Health Sciences, Antwerp University Hospital and Molecular Imaging and Radiology, University of Antwerp, Wilrijk, Belgium
| | - Chris Verslype
- Digestive Oncology, University Hospitals Leuven, Leuven, Belgium
| | - Koen Van Laere
- Nuclear Medicine, University Hospitals Leuven and Nuclear Medicine and Molecular Imaging,, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium", Campus Gasthuisberg, Nucleaire Geneeskunde, Herestraat 49, 3000, Leuven, Belgium
| | - Christophe M Deroose
- Nuclear Medicine, University Hospitals Leuven and Nuclear Medicine and Molecular Imaging,, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium", Campus Gasthuisberg, Nucleaire Geneeskunde, Herestraat 49, 3000, Leuven, Belgium.
| |
Collapse
|
2
|
Pauwels E, Cleeren F, Tshibangu T, Koole M, Serdons K, Boeckxstaens L, Dekervel J, Vandamme T, Lybaert W, Van den Broeck B, Laenen A, Clement PM, Geboes K, Van Cutsem E, Stroobants S, Verslype C, Bormans G, Deroose CM. 18F-AlF-NOTA-octreotide outperforms 68Ga-DOTA-TATE/-NOC PET in neuroendocrine tumor patients: results from a prospective, multicenter study. J Nucl Med 2022; 64:632-638. [PMID: 36265911 DOI: 10.2967/jnumed.122.264563] [Citation(s) in RCA: 19] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2022] [Revised: 10/04/2022] [Accepted: 10/04/2022] [Indexed: 11/16/2022] Open
Abstract
Fluorine-18-labeled somatostatin analogs (SSAs) could represent a valid alternative to the current gold standard gallium-68-labeled SSAs for somatostatin receptor (SSTR) imaging in patients with neuroendocrine tumors (NETs), given their logistical advantages. Recently, 18F-AlF-NOTA-octreotide (18F-AlF-OC) has emerged as a promising candidate, but a thorough comparison with 68Ga-DOTA-SSA in large patient groups is needed. This prospective, multicenter trial aims to demonstrate non-inferiority of 18F-AlF-OC compared with 68Ga-DOTA-SSA PET in NET patients (ClinicalTrials.gov: NCT04552847). Methods: Seventy-five patients with histologically confirmed NET and a routine clinical 68Ga-DOTATATE (n = 56) or 68Ga-DOTANOC (n = 19) PET, performed within a 3-month interval of the study scan (median: 7 days; range: -30 to +32 days), were included. Patients underwent a whole-body PET, two hours after IV injection of 4 MBq/kg 18F-AlF-OC. A randomized, blinded consensus read was performed by two experienced readers to count tumor lesions. Following unblinding, the detection ratio (DR) was determined for each scan, i.e. the fraction of lesions detected on a scan compared to the union of lesions of both scans. The differential detection ratio (DDR; difference in DR between 18F-AlF-OC and 68Ga-DOTATATE/NOC) per patient was calculated. Tracer uptake was evaluated by comparing SUVmax and tumor-to-background ratios (TBRs) in concordant lesions. Results: In total, 4709 different tumor lesions were detected, 3454 with 68Ga-DOTATATE/NOC and 4278 with 18F-AlF-OC. The mean DR with 18F-AlF-OC was significantly higher than with 68Ga-DOTATATE/NOC (91.1% vs. 75.3%; P<10-5). The resulting mean DDR was 15.8% with a lower margin of the 95% confidence interval (95% CI: 9.6%-22.0%) higher than -15%, the pre-specified boundary for non-inferiority. The mean DDR for the 68Ga-DOTATATE and 68Ga-DOTANOC subgroups were 11.8% (95% CI: 4.3-19.3) and 27.5% (95% CI: 17.8-37.1), respectively. The mean DDR for most organs was higher than zero, except for bone lesions (mean DDR -2.8% (95% CI: -17.8-12.2)). No significant differences in mean SUVmax were observed (P = 0.067), but mean TBR was significantly higher with 18F-AlF-OC than with 68Ga-DOTATATE/NOC (31.7±36.5 vs. 25.1±32.7; P = 0.001). Conclusion: 18F-AlF-OC is non-inferior and even superior compared with 68Ga-DOTATATE/NOC PET in NET patients. This validates 18F-AlF-OC as an option for clinical practice SSTR PET.
Collapse
Affiliation(s)
- Elin Pauwels
- University Hospitals Leuven & KU Leuven, Leuven, Belgium
| | | | | | - Michel Koole
- University Hospitals Leuven & KU Leuven, Leuven, Belgium
| | - Kim Serdons
- University Hospitals Leuven & KU Leuven, Leuven, Belgium
| | | | | | - Timon Vandamme
- Antwerp University Hospital & University of Antwerp, Antwerp Belgium
| | | | | | | | | | | | | | - Sigrid Stroobants
- Antwerp University Hospital & University of Antwerp, Antwerp Belgium
| | | | | | | |
Collapse
|
3
|
Vanderlinden G, Ceccarini J, Vande Casteele T, Michiels L, Lemmens R, Triau E, Serdons K, Tournoy J, Koole M, Vandenbulcke M, Van Laere K. Spatial decrease of synaptic density in amnestic mild cognitive impairment follows the tau build-up pattern. Mol Psychiatry 2022; 27:4244-4251. [PMID: 35794185 DOI: 10.1038/s41380-022-01672-x] [Citation(s) in RCA: 15] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/17/2022] [Revised: 06/03/2022] [Accepted: 06/10/2022] [Indexed: 02/07/2023]
Abstract
Next to amyloid and tau, synaptic loss is a key pathological hallmark in Alzheimer's disease, closely related to cognitive dysfunction and neurodegeneration. Tau is thought to cause synaptic loss, but this has not been experimentally verified in vivo. In a 2-year follow-up study, dual tracer PET-MR was performed in 12 amnestic MCI patients using 18F-MK-6240 for tau and 11C-UCB-J for SV2A as a proxy for synaptic density. Tau already accumulated in the neocortex at baseline with progression in Braak V/VI at follow-up. While synaptic loss was limited to limbic regions at baseline, it followed the specific tau pattern to stage IV/V regions two years later, indicating that tau spread might drive synaptic vulnerability. Moreover, synaptic density changes correlated to changes in cognitive function. This study shows for the first time in vivo that synaptic loss regionally follows tau accumulation after two years, providing a disease-modifying window of opportunity for (combined) tau-targeting therapies.
Collapse
Affiliation(s)
- Greet Vanderlinden
- Nuclear Medicine and Molecular Imaging, Imaging Pathology, KU Leuven, Leuven, Belgium.
| | - Jenny Ceccarini
- Nuclear Medicine and Molecular Imaging, Imaging Pathology, KU Leuven, Leuven, Belgium
| | - Thomas Vande Casteele
- Neuropsychiatry, Department of Neurosciences, Leuven Brain Institute, KU Leuven, Leuven, Belgium
| | - Laura Michiels
- Department of Neurosciences, KU Leuven, Leuven, Belgium.,Department of Neurology, University Hospitals UZ Leuven, Leuven, Belgium.,VIB, Center for Brain & Disease Research, Laboratory of Neurobiology, Leuven, Belgium
| | - Robin Lemmens
- Department of Neurosciences, KU Leuven, Leuven, Belgium.,Department of Neurology, University Hospitals UZ Leuven, Leuven, Belgium.,VIB, Center for Brain & Disease Research, Laboratory of Neurobiology, Leuven, Belgium
| | - Eric Triau
- Private Practice Neurology, Leuven, Belgium
| | - Kim Serdons
- Department of Nuclear Medicine, University Hospitals UZ Leuven, Leuven, Belgium
| | - Jos Tournoy
- Department of Geriatric Medicine, University Hospitals UZ Leuven, Leuven, Belgium.,Department of Public Health and Primary Care, Gerontology and Geriatrics, KU Leuven, Leuven, Belgium
| | - Michel Koole
- Nuclear Medicine and Molecular Imaging, Imaging Pathology, KU Leuven, Leuven, Belgium
| | - Mathieu Vandenbulcke
- Neuropsychiatry, Department of Neurosciences, Leuven Brain Institute, KU Leuven, Leuven, Belgium.,Department of Old-Age Psychiatry, University Hospitals UZ Leuven, Leuven, Belgium
| | - Koen Van Laere
- Nuclear Medicine and Molecular Imaging, Imaging Pathology, KU Leuven, Leuven, Belgium.,Department of Nuclear Medicine, University Hospitals UZ Leuven, Leuven, Belgium
| |
Collapse
|
4
|
Schaeverbeke J, Luckett ES, Gabel S, Reinartz M, De Meyer S, Cleynen I, Sleegers K, Van Broeckhoven C, Bormans G, Serdons K, Van Laere K, Dupont P, Vandenberghe R. Lack of association between bridging integrator 1 ( BIN1) rs744373 polymorphism and tau-PET load in cognitively intact older adults. Alzheimers Dement (N Y) 2022; 8:e12227. [PMID: 35229019 PMCID: PMC8864573 DOI: 10.1002/trc2.12227] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/22/2021] [Revised: 08/06/2021] [Accepted: 11/15/2021] [Indexed: 11/29/2022]
Abstract
INTRODUCTION The bridging integrator 1(BIN1) rs744373 risk polymorphism has been linked to increased [18F]AV1451 signal in non-demented older adults (ie., mild cognitive impairment [MCI] plus cognitively normal [CN] individuals). However, the association of BIN1 with in vivo tau, amyloid beta (Aβ) burden, and cognitive impairment in the asymptomatic stage of Alzheimer's disease (AD) remains unknown. METHODS The BIN1 effect on [18F]AV1451 binding was evaluated in 59 cognitively normal (CN) participants (39% apolipoprotein E [APOE ε4]) from the Flemish Prevent AD Cohort KU Leuven (F-PACK), as well as in 66 Alzheimer's Disease Neuroimaging Initiative (ADNI) CN participants, using voxelwise and regional statistics. For comparison, 52 MCI patients from ADNI were also studied. RESULTS Forty-four percent of F-PACK participants were BIN1 rs744373 risk-allele carriers, 21% showed high amyloid burden, and 8% had elevated [18F]AV1451 binding. In ADNI, 53% and 50% of CNs and MCIs, respectively, carried the BIN1 rs744373 risk-allele. Amyloid positivity was present in 23% of CNs and 51% of MCIs, whereas 2% of CNs and 35% of MCIs showed elevated [18F]AV1451 binding. There was no significant effect of BIN1 on voxelwise or regional [18F]AV1451 in F-PACK or ADNI CNs, or in the pooled CN sample. No significant association between BIN1 and [18F]AV1451 was obtained in ADNI MCI patients. However, in the MCI group, numerically higher [18F]AV1451 binding was observed in the BIN1 risk-allele group compared to the BIN1 normal group in regions corresponding to more progressed tau pathology. DISCUSSION We could not confirm the association between BIN1 rs744373 risk-allele and elevated [18F]AV1451 signal in CN older adults or MCI. Numerically higher [18F]AV1451 binding was observed, however, in the MCI BIN1 risk-allele group, indicating that the previously reported positive effect may be confounded by group. Therefore, when studying how the BIN1 risk polymorphism influences AD pathogenesis, a distinction should be made between asymptomatic, MCI, and dementia stages of AD.
Collapse
Affiliation(s)
- Jolien Schaeverbeke
- Department of Neurosciences, Laboratory for Cognitive NeurologyLeuven Brain Institute, KU LeuvenLeuvenBelgium
- Department of Imaging and Pathology, Laboratory of NeuropathologyLeuven Brain Institute, KU LeuvenLeuvenBelgium
| | - Emma S Luckett
- Department of Neurosciences, Laboratory for Cognitive NeurologyLeuven Brain Institute, KU LeuvenLeuvenBelgium
| | - Silvy Gabel
- Department of Neurosciences, Laboratory for Cognitive NeurologyLeuven Brain Institute, KU LeuvenLeuvenBelgium
| | - Mariska Reinartz
- Department of Neurosciences, Laboratory for Cognitive NeurologyLeuven Brain Institute, KU LeuvenLeuvenBelgium
| | - Steffi De Meyer
- Department of Neurosciences, Laboratory for Molecular Neurobiomarker ResearchLeuven Brain Institute, KU LeuvenLeuvenBelgium
| | | | - Kristel Sleegers
- VIB‐UAntwerp Center for Molecular NeurologyAntwerpBelgium
- Department of Biomedical SciencesUniversity of AntwerpAntwerpBelgium
| | - Christine Van Broeckhoven
- VIB‐UAntwerp Center for Molecular NeurologyAntwerpBelgium
- Department of Biomedical SciencesUniversity of AntwerpAntwerpBelgium
| | - Guy Bormans
- Laboratory for Radiopharmaceutical ResearchKU LeuvenLeuvenBelgium
| | - Kim Serdons
- Division of Nuclear MedicineUZ LeuvenLeuvenBelgium
| | - Koen Van Laere
- Division of Nuclear MedicineUZ LeuvenLeuvenBelgium
- Department of Imaging and Pathology, Nuclear Medicine and Molecular ImagingKU LeuvenLeuvenBelgium
| | - Patrick Dupont
- Department of Neurosciences, Laboratory for Cognitive NeurologyLeuven Brain Institute, KU LeuvenLeuvenBelgium
| | - Rik Vandenberghe
- Department of Neurosciences, Laboratory for Cognitive NeurologyLeuven Brain Institute, KU LeuvenLeuvenBelgium
- Department of NeurologyUZ LeuvenLeuvenBelgium
| | | |
Collapse
|
5
|
Li W, Wang Y, Lohith TG, Zeng Z, Tong L, Mazzola R, Riffel K, Miller P, Purcell M, Holahan M, Haley H, Gantert L, Hesk D, Ren S, Morrow J, Uslaner J, Struyk A, Wai JMC, Rudd MT, Tellers DM, McAvoy T, Bormans G, Koole M, Van Laere K, Serdons K, de Hoon J, Declercq R, De Lepeleire I, Pascual MB, Zanotti-Fregonara P, Yu M, Arbones V, Masdeu JC, Cheng A, Hussain A, Bueters T, Anderson MS, Hostetler ED, Basile AS. The PET tracer [ 11C]MK-6884 quantifies M4 muscarinic receptor in rhesus monkeys and patients with Alzheimer's disease. Sci Transl Med 2022; 14:eabg3684. [PMID: 35020407 DOI: 10.1126/scitranslmed.abg3684] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
[Figure: see text].
Collapse
Affiliation(s)
- Wenping Li
- MRL, Merck & Co. Inc., Kenilworth, NJ 07033, USA
| | - Yuchuan Wang
- MRL, Merck & Co. Inc., Kenilworth, NJ 07033, USA
| | | | - Zhizhen Zeng
- MRL, Merck & Co. Inc., Kenilworth, NJ 07033, USA
| | - Ling Tong
- MRL, Merck & Co. Inc., Kenilworth, NJ 07033, USA
| | | | - Kerry Riffel
- MRL, Merck & Co. Inc., Kenilworth, NJ 07033, USA
| | | | - Mona Purcell
- MRL, Merck & Co. Inc., Kenilworth, NJ 07033, USA
| | | | - Hyking Haley
- MRL, Merck & Co. Inc., Kenilworth, NJ 07033, USA
| | - Liza Gantert
- MRL, Merck & Co. Inc., Kenilworth, NJ 07033, USA
| | - David Hesk
- MRL, Merck & Co. Inc., Kenilworth, NJ 07033, USA
| | - Sumei Ren
- MRL, Merck & Co. Inc., Kenilworth, NJ 07033, USA
| | - John Morrow
- MRL, Merck & Co. Inc., Kenilworth, NJ 07033, USA
| | | | - Arie Struyk
- MRL, Merck & Co. Inc., Kenilworth, NJ 07033, USA
| | | | | | | | | | - Guy Bormans
- Laboratory for Radiopharmaceutical Research, KU Leuven, 3001 Leuven, Belgium
| | - Michel Koole
- Nuclear Medicine and Molecular Imaging, KU Leuven and University Hospital Leuven, 3001 Leuven, Belgium
| | - Koen Van Laere
- Nuclear Medicine and Molecular Imaging, KU Leuven and University Hospital Leuven, 3001 Leuven, Belgium
| | - Kim Serdons
- Nuclear Medicine and Molecular Imaging, KU Leuven and University Hospital Leuven, 3001 Leuven, Belgium
| | - Jan de Hoon
- Center for Clinical Pharmacology, KU Leuven, 3001 Leuven, Belgium
| | - Ruben Declercq
- Translational Pharmacology Europe, MSD (Europe) Inc., 1200 Brussels, Belgium
| | - Inge De Lepeleire
- Translational Pharmacology Europe, MSD (Europe) Inc., 1200 Brussels, Belgium
| | - Maria B Pascual
- Nantz National Alzheimer Center, Houston Methodist Neurological Institute, Houston, TX 77030, USA.,Department of Neurology, Weill Cornell Medicine, New York, NY 10065, USA
| | - Paolo Zanotti-Fregonara
- Nantz National Alzheimer Center, Houston Methodist Neurological Institute, Houston, TX 77030, USA.,Department of Neurology, Weill Cornell Medicine, New York, NY 10065, USA
| | - Meixiang Yu
- Nantz National Alzheimer Center, Houston Methodist Neurological Institute, Houston, TX 77030, USA.,Department of Neurology, Weill Cornell Medicine, New York, NY 10065, USA
| | - Victoria Arbones
- Nantz National Alzheimer Center, Houston Methodist Neurological Institute, Houston, TX 77030, USA
| | - Joseph C Masdeu
- Nantz National Alzheimer Center, Houston Methodist Neurological Institute, Houston, TX 77030, USA.,Department of Neurology, Weill Cornell Medicine, New York, NY 10065, USA
| | - Amy Cheng
- MRL, Merck & Co. Inc., Kenilworth, NJ 07033, USA
| | | | | | | | | | | |
Collapse
|
6
|
Cawthorne C, Maguire P, Mercier J, Sciberras D, Serdons K, Bormans G, de Hoon J, Van Laere K, Koole M. Human biodistribution and dosimetry of [ 11C]-UCB-J, a PET radiotracer for imaging synaptic density. EJNMMI Phys 2021; 8:37. [PMID: 33891195 PMCID: PMC8065069 DOI: 10.1186/s40658-021-00384-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2020] [Accepted: 04/13/2021] [Indexed: 11/10/2022] Open
Abstract
RATIONALE [11C]-UCB-J is an emerging tool for the noninvasive measurement of synaptic vesicle density in vivo. Here, we report human biodistribution and dosimetry estimates derived from sequential whole-body PET using two versions of the OLINDA dosimetry program. METHODS Sequential whole-body PET scans were performed in 3 healthy subjects for 2 h after injection of 254 ± 77 MBq [11C]-UCB-J. Volumes of interest were drawn over relevant source organs to generate time-activity curves and calculate time-integrated activity coefficients, with effective dose coefficients calculated using OLINDA 2.1 and compared to values derived from OLINDA 1.1 and those recently reported in the literature. RESULTS [11C]-UCB-J administration was safe and showed mixed renal and hepatobiliary clearance, with largest organ absorbed dose coefficients for the urinary bladder wall and small intestine (21.7 and 23.5 μGy/MBq, respectively). The average (±SD) effective dose coefficient was 5.4 ± 0.7 and 5.1 ± 0.8 μSv/MBq for OLINDA versions 1.1 and 2.1 respectively. Doses were lower than previously reported in the literature using either software version. CONCLUSIONS A single IV administration of 370 MBq [11C]-UCB-J corresponds to an effective dose of less than 2.0 mSv, enabling multiple PET examinations to be carried out in the same subject. TRIAL REGISTRATION EudraCT number: 2016-001190-32. Registered 16 March 2016, no URL available for phase 1 trials.
Collapse
Affiliation(s)
- Christopher Cawthorne
- Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium
| | | | | | | | - Kim Serdons
- Division of Nuclear Medicine, University Hospitals Leuven, Leuven, Belgium
| | - Guy Bormans
- Laboratory for Radiopharmaceutical Research, KU Leuven, Leuven, Belgium
| | - Jan de Hoon
- Center for Clinical Pharmacology, University Hospitals Leuven, Leuven, Belgium
| | - Koen Van Laere
- Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.,Division of Nuclear Medicine, University Hospitals Leuven, Leuven, Belgium
| | - Michel Koole
- Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.
| |
Collapse
|
7
|
Celen S, Rokka J, Gilbert TM, Koole M, Vermeulen I, Serdons K, Schroeder FA, Wagner FF, Bleeser T, Hightower BG, Hu J, Rahal D, Beyzavi H, Vanduffel W, Van Laere K, Kranz JE, Hooker JM, Bormans G, Cawthorne CJ. Translation of HDAC6 PET Imaging Using [ 18F]EKZ-001-cGMP Production and Measurement of HDAC6 Target Occupancy in Nonhuman Primates. ACS Chem Neurosci 2020; 11:1093-1101. [PMID: 32159328 DOI: 10.1021/acschemneuro.0c00074] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Histone deacetylase 6 (HDAC6) is a multifunctional cytoplasmic enzyme involved in diverse cellular processes such as intracellular transport and protein quality control. Inhibition of HDAC6 can alleviate defects in cell and rodent models of certain diseases, particularly neurodegenerative disorders, including Alzheimer's disease and amyotrophic lateral sclerosis. However, while HDAC6 represents a potentially powerful therapeutic target, development of effective brain-penetrant HDAC6 inhibitors remains challenging. Recently, [18F]EKZ-001 ([18F]Bavarostat), a brain-penetrant positron emission tomography (PET) radioligand with high affinity and selectivity toward HDAC6, was developed and evaluated preclinically for its ability to bind HDAC6. Herein, we describe the efficient and robust fully automated current Good Manufacturing Practices (cGMP) compliant production method. [18F]EKZ-001 quantification methods were validated in nonhuman primates (NHP) using full kinetic modeling, and [18F]EKZ-001 PET was applied to compare dose-occupancy relationships between two HDAC6 inhibitors, EKZ-317 and ACY-775. [18F]EKZ-001 is cGMP produced with an average decay-corrected radiochemical yield of 14% and an average molar activity of 204 GBq/μmol. We demonstrate that a two-tissue compartmental model and Logan graphical analysis are appropriate for [18F]EKZ-001 PET quantification in NHP brain. Blocking studies show that the novel compound EKZ-317 achieves higher target occupancy than ACY-775. This work supports the translation of [18F]EKZ-001 PET for first-in-human studies.
Collapse
Affiliation(s)
- Sofie Celen
- Laboratory for Radiopharmaceutical Research, KU Leuven, Herestraat 49, 3000 Leuven, Belgium
| | - Johanna Rokka
- Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, Massachusetts 02129, United States
| | - Tonya M. Gilbert
- Eikonizo Therapeutics, Inc., Cambridge, Massachusetts 02139, United States
| | - Michel Koole
- Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, 3000 Leuven, Belgium
| | - Isabeau Vermeulen
- Laboratory for Radiopharmaceutical Research, KU Leuven, Herestraat 49, 3000 Leuven, Belgium
| | - Kim Serdons
- Division of Nuclear Medicine, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium
| | | | - Florence F. Wagner
- Center for the Development of Therapeutics, Stanley Center for Psychiatric Research, The Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02139, United States
| | - Tom Bleeser
- Anesthesiology and Algology, KU Leuven, Herestraat 49, 3000 Leuven, Belgium
| | - Baileigh G. Hightower
- Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, Massachusetts 02129, United States
| | - Jiyun Hu
- Department of Chemistry and Biochemistry, University of Arkansas, Fayetteville, Arkansas 72701, United States
| | - Dania Rahal
- Department of Chemistry and Biochemistry, University of Arkansas, Fayetteville, Arkansas 72701, United States
| | - Hudson Beyzavi
- Department of Chemistry and Biochemistry, University of Arkansas, Fayetteville, Arkansas 72701, United States
| | - Wim Vanduffel
- Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, Massachusetts 02129, United States
- Laboratory for Neuro- and Psychophysiology, KU Leuven, Herestraat 49, 3000 Leuven, Belgium
| | - Koen Van Laere
- Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, 3000 Leuven, Belgium
- Division of Nuclear Medicine, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium
| | - Janice E. Kranz
- Eikonizo Therapeutics, Inc., Cambridge, Massachusetts 02139, United States
| | - Jacob M. Hooker
- Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, Massachusetts 02129, United States
| | - Guy Bormans
- Laboratory for Radiopharmaceutical Research, KU Leuven, Herestraat 49, 3000 Leuven, Belgium
| | - Christopher J. Cawthorne
- Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, 3000 Leuven, Belgium
| |
Collapse
|
8
|
Tshibangu T, Cawthorne C, Serdons K, Pauwels E, Gsell W, Bormans G, Deroose CM, Cleeren F. Automated GMP compliant production of [ 18F]AlF-NOTA-octreotide. EJNMMI Radiopharm Chem 2020; 5:4. [PMID: 31997090 PMCID: PMC6989705 DOI: 10.1186/s41181-019-0084-1] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2019] [Accepted: 12/16/2019] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND Gallium-68 labeled synthetic somatostatin analogs for PET/CT imaging are the current gold standard for somatostatin receptor imaging in neuroendocrine tumor patients. Despite good imaging properties, their use in clinical practice is hampered by the low production levels of 68Ga eluted from a 68Ge/68Ga generator. In contrast, 18F-tracers can be produced in large quantities allowing centralized production and distribution to distant PET centers. [18F]AlF-NOTA-octreotide is a promising tracer that combines a straightforward Al18F-based production procedure with excellent in vivo pharmacokinetics and specific tumor uptake, demonstrated in SSTR2 positive tumor mice. However, advancing towards clinical studies with [18F]AlF-NOTA-octreotide requires the development of an efficient automated GMP production process and additional preclinical studies are necessary to further evaluate the in vivo properties of [18F]AlF-NOTA-octreotide. In this study, we present the automated GMP production of [18F]AlF-NOTA-octreotide on the Trasis AllinOne® radio-synthesizer platform and quality control of the drug product in accordance with GMP. Further, radiometabolite studies were performed and the pharmacokinetics and biodistribution of [18F]AlF-NOTA-octreotide were assessed in healthy rats using μPET/MR. RESULTS The production process of [18F]AlF-NOTA-octreotide has been validated by three validation production runs and the tracer was obtained with a final batch activity of 10.8 ± 1.3 GBq at end of synthesis with a radiochemical yield of 26.1 ± 3.6% (dc), high radiochemical purity and stability (96.3 ± 0.2% up to 6 h post synthesis) and an apparent molar activity of 160.5 ± 75.3 GBq/μmol. The total synthesis time was 40 ± 3 min. Further, the quality control was successfully implemented using validated analytical procedures. Finally, [18F]AlF-NOTA-octreotide showed high in vivo stability and favorable pharmacokinetics with high and specific accumulation in SSTR2-expressing organs in rats. CONCLUSION This robust and automated production process provides high batch activity of [18F]AlF-NOTA-octreotide allowing centralized production and shipment of the compound to remote PET centers. Further, the production process and quality control developed for [18F]AlF-NOTA-octreotide is easily implementable in a clinical setting and the tracer is a potential clinical alternative for somatostatin directed 68Ga labeled peptides obviating the need for a 68Ge/68Ga-generator. Finally, the favorable in vivo properties of [18F]AlF-NOTA-octreotide in rats, with high and specific accumulation in SSTR2 expressing organs, supports clinical translation.
Collapse
Affiliation(s)
- Térence Tshibangu
- Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Herestraat 49 Box 821, 3000 Leuven, Belgium
| | - Christopher Cawthorne
- Nuclear Medicine, University Hospitals Leuven, Leuven, Belgium
- Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium
- Biomedical MRI/MoSAIC, Department of Imaging and Pathology, Biomedical Sciences Group, KU Leuven, Leuven, Belgium
| | - Kim Serdons
- Nuclear Medicine, University Hospitals Leuven, Leuven, Belgium
| | - Elin Pauwels
- Nuclear Medicine, University Hospitals Leuven, Leuven, Belgium
- Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium
| | - Willy Gsell
- Biomedical MRI/MoSAIC, Department of Imaging and Pathology, Biomedical Sciences Group, KU Leuven, Leuven, Belgium
| | - Guy Bormans
- Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Herestraat 49 Box 821, 3000 Leuven, Belgium
| | - Christophe M. Deroose
- Nuclear Medicine, University Hospitals Leuven, Leuven, Belgium
- Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium
| | - Frederik Cleeren
- Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Herestraat 49 Box 821, 3000 Leuven, Belgium
| |
Collapse
|
9
|
Schaeverbeke J, Celen S, Cornelis J, Ronisz A, Serdons K, Van Laere K, Thal DR, Tousseyn T, Bormans G, Vandenberghe R. Binding of [ 18F]AV1451 in post mortem brain slices of semantic variant primary progressive aphasia patients. Eur J Nucl Med Mol Imaging 2019; 47:1949-1960. [PMID: 31848674 PMCID: PMC7300115 DOI: 10.1007/s00259-019-04631-x] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2019] [Accepted: 11/18/2019] [Indexed: 12/31/2022]
Abstract
Purpose In vivo tau-PET tracer retention in the anterior temporal lobe of patients with semantic variant primary progressive aphasia (SV PPA) has consistently been reported. This is unexpected as the majority of these patients have frontotemporal lobar degeneration TDP (FTLD-TDP). Methods We conducted an in vitro [18F]AV1451 autoradiography binding study in five cases with a clinical diagnosis of SV PPA constituting the range of pathologies (i.e., three FTLD-TDP, one Alzheimer’s disease (AD), and one Pick’s disease (PiD)). Binding was compared with two controls without neurodegeneration, two typical AD, one corticobasal syndrome with underlying AD, and one frontotemporal dementia behavioral variant with FTLD-TDP. The effect of blocking with the authentic reference material and with the MAO-B inhibitor deprenyl was assessed. Immunohistochemistry was performed on adjacent cryosections. Results Absence of specific [18F]AV1451 binding was observed for all three SV PPA FTLD-TDP cases. The absence of binding in controls as well as the successful blocking with authentic AV1451 in cases with tauopathy demonstrated specificity of the [18F]AV1451 signal for tau. The specific [18F]AV1451 binding was highest in AD, followed by PiD. This binding colocalized with the respective tau lesions and could not be blocked by deprenyl. Similar pilot findings were obtained with [18F]THK5351. Conclusion In vitro autoradiography showed no [18F]AV1451 binding in SV PPA due to FTLD-TDP, while specific binding was present in SV PPA due to AD and PiD. The discrepancy between in vitro and in vivo findings remains to be explained. The discordance is not related to [18F]AV1451 idiosyncrasies as [18F]THK5351 findings were similar. Electronic supplementary material The online version of this article (10.1007/s00259-019-04631-x) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Jolien Schaeverbeke
- Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Herestraat 49, 3000, Leuven, Belgium
| | - Sofie Celen
- Laboratory of Radiopharmaceutical Research, KU Leuven, Herestraat 49, 3000, Leuven, Belgium
| | - Julie Cornelis
- Laboratory of Radiopharmaceutical Research, KU Leuven, Herestraat 49, 3000, Leuven, Belgium
| | - Alicja Ronisz
- Laboratory for Pathology, Department of Imaging and Pathology, KU Leuven, Herestraat 49, 3000, Leuven, Belgium.,Leuven Brain Institute, Herestraat 49, 3000, Leuven, Belgium
| | - Kim Serdons
- Nuclear Medicine and Molecular Imaging, University HospitalsLeuven, Herestraat 49, 3000, Leuven, Belgium
| | - Koen Van Laere
- Nuclear Medicine and Molecular Imaging, University HospitalsLeuven, Herestraat 49, 3000, Leuven, Belgium
| | - Dietmar Rudolf Thal
- Laboratory for Pathology, Department of Imaging and Pathology, KU Leuven, Herestraat 49, 3000, Leuven, Belgium.,Leuven Brain Institute, Herestraat 49, 3000, Leuven, Belgium.,Pathology division, Department of Pathology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium
| | - Thomas Tousseyn
- Laboratory for Pathology, Department of Imaging and Pathology, KU Leuven, Herestraat 49, 3000, Leuven, Belgium.,Pathology division, Department of Pathology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium
| | - Guy Bormans
- Laboratory of Radiopharmaceutical Research, KU Leuven, Herestraat 49, 3000, Leuven, Belgium
| | - Rik Vandenberghe
- Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Herestraat 49, 3000, Leuven, Belgium. .,Neurology division, Department of Neurology, University Hospitals Leuven, Herestraat 49 box 7003, 3000, Leuven, Belgium.
| |
Collapse
|
10
|
Van Weehaeghe D, Koole M, Schmidt ME, Deman S, Jacobs AH, Souche E, Serdons K, Sunaert S, Bormans G, Vandenberghe W, Van Laere K. [ 11C]JNJ54173717, a novel P2X7 receptor radioligand as marker for neuroinflammation: human biodistribution, dosimetry, brain kinetic modelling and quantification of brain P2X7 receptors in patients with Parkinson's disease and healthy volunteers. Eur J Nucl Med Mol Imaging 2019; 46:2051-2064. [PMID: 31243495 DOI: 10.1007/s00259-019-04369-6] [Citation(s) in RCA: 43] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2019] [Accepted: 05/23/2019] [Indexed: 01/11/2023]
Abstract
PURPOSE The P2X7 receptor (P2X7R) is an ATP-gated ion channel predominantly expressed on activated microglia and is important in neurodegenerative diseases including Parkinson's disease (PD). In this first-in-human study, we investigated [11C]JNJ54173717 ([11C]JNJ717), a selective P2X7R tracer, in healthy volunteers (HV) and PD patients. Biodistribution, dosimetry, kinetic modelling and short-term test-retest variation (TRV), as well as possible genotype effects, were investigated. METHODS Biodistribution and radiation dosimetry studies were performed in three HV (mean age 30 ± 2 years, two women) using whole-body PET/CT. The most appropriate kinetic model was determined in 11 HV (mean age 62 ± 10 years, six women) and 10 PD patients (mean age 64 ± 8 years, three women; mean UPDRS motor score 21 ± 8) using 90-min dynamic simultaneous PET/MR scans. The total volume of distribution (VT) was calculated using a one-tissue and a two-tissue compartment model (1TCM, 2TCM) and Logan graphical analysis, and its time stability was assessed. Seven subjects underwent retest scans (mean age 60 ± 13 years, four HV, one woman). A group analysis was performed to compare PD patients and HV. Finally, 13 exons of P2X7R were genotyped in all subjects included in the second part of the study. RESULTS The mean effective dose was 4.47 ± 0.32 μSv/MBq, with the highest absorbed doses to the gallbladder, liver and small intestine. A reversible 2TCM was the most appropriate kinetic model with relatively homogeneous VT values in the grey and white matter. Average VT values were 3.4 ± 0.8 in HV and 3.3 ± 0.7 in PD patients, with no significant difference between the groups, but a possible genotype effect (rs3751143) was identified which can affect VT. Average TRV was 10-15%. The stability of VT over time allowed a reduction in scan time to 70 min. CONCLUSION [11C]JNJ717 is safe and suitable for quantifying P2X7R expression in human brain. In this pilot study, no significant differences in P2X7R binding were found between HV and PD patients. The results also suggest that genotype effects need to be incorporated in future P2X7R PET analyses.
Collapse
Affiliation(s)
- Donatienne Van Weehaeghe
- Division of Nuclear Medicine and Molecular Imaging, University Hospitals of Leuven and KU Leuven, Leuven, Belgium.
| | - Michel Koole
- Division of Nuclear Medicine and Molecular Imaging, University Hospitals of Leuven and KU Leuven, Leuven, Belgium
| | - Mark E Schmidt
- Janssen Research and Development: Beerse, Beerse, Belgium
| | - Stephanie Deman
- Genomics Core, UZ Leuven, Leuven, Belgium
- Department of Human Genetics, KU Leuven, Leuven, Belgium
| | - Andreas H Jacobs
- European Institute for Molecular Imaging (EIMI), Westfalian Wilhelms University (WWU) Münster, Münster, Germany
- Department of Geriatrics and Neurology, Johanniter Hospital Bonn, Bonn, Germany
| | - Erika Souche
- Genomics Core, UZ Leuven, Leuven, Belgium
- Department of Human Genetics, KU Leuven, Leuven, Belgium
| | - Kim Serdons
- Division of Nuclear Medicine and Molecular Imaging, University Hospitals of Leuven and KU Leuven, Leuven, Belgium
| | - Stefan Sunaert
- Department of Radiology, University Hospitals Leuven, Gasthuisberg, UZ, Leuven, Belgium
| | - Guy Bormans
- Laboratory for Radiopharmaceutical Research, KU Leuven, Leuven, Belgium
| | - Wim Vandenberghe
- Department of Neurosciences, KU Leuven, Leuven, Belgium
- Department of Neurology, University Hospitals Leuven, Leuven, Belgium
| | - Koen Van Laere
- Division of Nuclear Medicine and Molecular Imaging, University Hospitals of Leuven and KU Leuven, Leuven, Belgium
| |
Collapse
|
11
|
Pauwels E, Cleeren F, Tshibangu T, Koole M, Serdons K, Dekervel J, Van Cutsem E, Verslype C, Van Laere K, Bormans G, Deroose CM. Al18F-NOTA-octreotide: first comparison with 68Ga-DOTATATE in a neuroendocrine tumour patient. Eur J Nucl Med Mol Imaging 2019; 46:2398-2399. [DOI: 10.1007/s00259-019-04425-1] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2019] [Accepted: 07/02/2019] [Indexed: 10/26/2022]
|
12
|
Schaeverbeke J, Celen S, Ronisz A, Serdons K, Thal D, Bormans G, Vandenberghe R. P2-350: POSTMORTEM BINDING STUDY OF [ 18
F]-AV1451 AND [ 18
F]-THK5351 IN SEMANTIC VARIANT PRIMARY PROGRESSIVE APHASIA. Alzheimers Dement 2019. [DOI: 10.1016/j.jalz.2019.06.2757] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Affiliation(s)
- Jolien Schaeverbeke
- Alzheimer Research Centre KU Leuven; Leuven Research Institute for Neurodegenerative Disorders; Leuven Belgium
- Laboratory for Cognitive Neurology, Department of Neurosciences; KU Leuven; Leuven Belgium
| | - Sofie Celen
- Radiopharmaceutical Research, Department of Pharmacology; KU Leuven; Leuven Belgium
| | - Alicja Ronisz
- Laboratory for Neuropathology, Department of Neurosciences; KU Leuven; Leuven Belgium
| | - Kim Serdons
- Nuclear Medicine; KU Leuven and University Hospital Leuven; Leuven Belgium
| | - Dietmar Thal
- Laboratory for Neuropathology, Department of Neurosciences; KU Leuven; Leuven Belgium
| | - Guy Bormans
- Radiopharmaceutical Research, Department of Pharmacology; KU Leuven; Leuven Belgium
- Nuclear Medicine and Molecular Imaging; KU Leuven and UZ Leuven; Leuven Belgium
| | - Rik Vandenberghe
- Alzheimer Research Centre KU Leuven; Leuven Research Institute for Neurodegenerative Disorders; Leuven Belgium
- Laboratory for Cognitive Neurology, Department of Neurosciences; KU Leuven; Leuven Belgium
- Neurology Department; University Hospitals Leuven (UZ Leuven, Campus Gasthuisberg); Leuven Belgium
| |
Collapse
|
13
|
Vandenberghe R, Gabel S, Schaeverbeke J, Sleegers K, Van Broeckhoven C, Bormans G, Serdons K, Dupont P, Van Laere K. O5‐07‐02: APOLIPOPROTEIN E AND BIN1 POLYMORPHISMS DIFFERENTIALLY AFFECT CORTICAL AMYLOID AND TAU LOAD IN HEALTHY OLDER ADULTS. Alzheimers Dement 2019. [DOI: 10.1016/j.jalz.2019.06.4871] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Affiliation(s)
- Rik Vandenberghe
- KU Leuven Leuven Belgium
- University Hospital of Leuven Leuven Belgium
| | - Silvy Gabel
- Alzheimer Research Centre KU Leuven Leuven Belgium
- University of Leuven Leuven Belgium
| | - Jolien Schaeverbeke
- Alzheimer Research Centre KU Leuven Leuven Research Institute for Neurodegenerative Disorders Leuven Belgium
- Laboratory for Cognitive Neurology, Department of Neurosciences KU Leuven Leuven Belgium
| | - Kristel Sleegers
- Laboratory of Neurogenetics, Institute Born-Bunge University of Antwerp Antwerp Belgium
- Neurodegenerative Brain Diseases group VIB – University of Antwerp Center for Molecular Neurology Antwerp Belgium
- Institute Born-Bunge University of Antwerp Antwerp Belgium
| | - Christine Van Broeckhoven
- Neurodegenerative Brain Diseases group, Center for Molecular Neurology VIB Antwerp Belgium
- Institute Born-Bunge, Laboratory of Neurogenetics University of Antwerp Antwerp Belgium
| | - Guy Bormans
- Nuclear Medicine and Molecular Imaging KU Leuven and UZ Leuven Leuven Belgium
- Radiopharmaceutical Research, Department of Pharmacology KU Leuven Leuven Belgium
| | - Kim Serdons
- Nuclear Medicine KU Leuven and University Hospital Leuven Leuven Belgium
| | | | | |
Collapse
|
14
|
Koole M, Schmidt ME, Hijzen A, Ravenstijn P, Vandermeulen C, Van Weehaeghe D, Serdons K, Celen S, Bormans G, Ceusters M, Zhang W, Van Nueten L, Kolb H, de Hoon J, Van Laere K. 18F-JNJ-64413739, a Novel PET Ligand for the P2X7 Ion Channel: Radiation Dosimetry, Kinetic Modeling, Test-Retest Variability, and Occupancy of the P2X7 Antagonist JNJ-54175446. J Nucl Med 2018; 60:683-690. [PMID: 30262518 DOI: 10.2967/jnumed.118.216747] [Citation(s) in RCA: 43] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2018] [Accepted: 09/18/2018] [Indexed: 12/27/2022] Open
Abstract
The P2X7 receptor (P2X7R) is an adenosine triphosphate-gated ion channel that is predominantly expressed on microglial cells in the central nervous system. We report the clinical qualification of P2X7-specific PET ligand 18F-JNJ-64413739 in healthy volunteers, including dosimetry, kinetic modeling, test-retest variability, and blocking by the P2X7 antagonist JNJ-54175446. Methods: Whole-body dosimetry was performed in 3 healthy male subjects by consecutive whole-body PET/CT scanning, estimation of the normalized cumulated activity, and calculation of the effective dose using OLINDA (v1.1). Next, 5 healthy male subjects underwent a 120-min dynamic 18F-JNJ-64413739 PET/MRI scan with arterial blood sampling to determine the appropriate kinetic model. For this purpose, 1- and 2-tissue compartment models and Logan graphic analysis (LGA) were evaluated for estimating regional volumes of distribution (VT). PET/MRI scanning was repeated in 4 of these subjects to evaluate medium-term test-retest variability (interscan interval, 26-97 d). For the single-dose occupancy study, 8 healthy male subjects underwent baseline and postdose 18F-JNJ-64413739 PET/MRI scans 4-6 h after the administration of a single oral dose of JNJ-54175446 (dose range, 5-300 mg). P2X7 occupancies were estimated using a Lassen plot and regional baseline and postdose VT Results: The average (mean ± SD) effective dose was 22.0 ± 1.0 μSv/MBq. The 2-tissue compartment model was the most appropriate kinetic model, with LGA showing very similar results. Regional 2-tissue compartment model VT values were about 3 and were rather homogeneous across all brain regions, with slightly higher estimates for the thalamus, striatum, and brain stem. Between-subject VT variability was relatively high, with cortical VT showing an approximate 3-fold range across subjects. As for time stability, the acquisition time could be reduced to 90 min. The average regional test-retest variability values were 10.7% ± 2.2% for 2-tissue compartment model VT and 11.9% ± 2.2% for LGA VT P2X7 occupancy approached saturation for single doses of JNJ-54175446 higher than 50 mg, and no reference region could be identified. Conclusion: 18F-JNJ-64413739 is a suitable PET ligand for the quantification of P2X7R expression in the human brain. It can be used to provide insight into P2X7R expression in health and disease, to evaluate target engagement by P2X7 antagonists, and to guide dose selection.
Collapse
Affiliation(s)
- Michel Koole
- Division of Nuclear Medicine and Molecular Imaging, University Hospitals Leuven, Leuven, Belgium.,Department of Imaging and Pathology, KU Leuven, Leuven, Belgium
| | | | - Anja Hijzen
- Janssen Research and Development, Beerse, Belgium
| | | | - Corinne Vandermeulen
- Center for Clinical Pharmacology, University Hospitals Leuven, Leuven, Belgium; and
| | - Donatienne Van Weehaeghe
- Division of Nuclear Medicine and Molecular Imaging, University Hospitals Leuven, Leuven, Belgium
| | - Kim Serdons
- Division of Nuclear Medicine and Molecular Imaging, University Hospitals Leuven, Leuven, Belgium
| | - Sofie Celen
- Laboratory for Radiopharmaceutical Research, KU Leuven, Leuven, Belgium
| | - Guy Bormans
- Laboratory for Radiopharmaceutical Research, KU Leuven, Leuven, Belgium
| | | | - Wei Zhang
- Janssen Research and Development, Beerse, Belgium
| | | | | | - Jan de Hoon
- Center for Clinical Pharmacology, University Hospitals Leuven, Leuven, Belgium; and
| | - Koen Van Laere
- Division of Nuclear Medicine and Molecular Imaging, University Hospitals Leuven, Leuven, Belgium .,Department of Imaging and Pathology, KU Leuven, Leuven, Belgium
| |
Collapse
|
15
|
Lohith TG, Bennacef I, Vandenberghe R, Vandenbulcke M, Salinas CA, Declercq R, Reynders T, Telan-Choing NF, Riffel K, Celen S, Serdons K, Bormans G, Tsai K, Walji A, Hostetler ED, Evelhoch JL, Van Laere K, Forman M, Stoch A, Sur C, Struyk A. Brain Imaging of Alzheimer Dementia Patients and Elderly Controls with 18F-MK-6240, a PET Tracer Targeting Neurofibrillary Tangles. J Nucl Med 2018; 60:107-114. [PMID: 29880509 DOI: 10.2967/jnumed.118.208215] [Citation(s) in RCA: 79] [Impact Index Per Article: 13.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2018] [Accepted: 05/14/2018] [Indexed: 11/16/2022] Open
Abstract
18F-MK-6240 (18F-labeled 6-(fluoro)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine) is a highly selective, subnanomolar-affinity PET tracer for imaging neurofibrillary tangles (NFTs). Plasma kinetics, brain uptake, and preliminary quantitative analysis of 18F-MK-6240 in healthy elderly (HE) subjects, subjects with clinically probable Alzheimer disease (AD), and subjects with amnestic mild cognitive impairment were characterized in a study that is, to our knowledge, the first to be performed on humans. Methods: Dynamic PET scans of up to 150 min were performed on 4 cognitively normal HE subjects, 4 AD subjects, and 2 amnestic mild cognitive impairment subjects after a bolus injection of 152-169 MBq of 18F-MK-6240 to evaluate tracer kinetics and distribution in brain. Regional SUV ratio (SUVR) and distribution volume ratio were determined using the cerebellar cortex as a reference region. Total distribution volume was assessed by compartmental modeling using radiometabolite-corrected input function in a subgroup of 6 subjects. Results: 18F-MK-6240 had rapid brain uptake with a peak SUV of 3-5, followed by a uniformly quick washout from all brain regions in HE subjects; slower clearance was observed in regions commonly associated with NFT deposition in AD subjects. In AD subjects, SUVR between 60 and 90 min after injection was high (approximately 2-4) in regions associated with NFT deposition, whereas in HE subjects, SUVR was approximately 1 across all brain regions, suggesting high tracer selectivity for binding NFTs in vivo. 18F-MK-6240 total distribution volume was approximately 2- to 3-fold higher in neocortical and medial temporal brain regions of AD subjects than in HE subjects and stabilized by 60 min in both groups. Distribution volume ratio estimated by the Logan reference tissue model or compartmental modeling correlated well (R 2 > 0.9) to SUVR from 60 to 90 min for AD subjects. Conclusion: 18F-MK-6240 exhibited favorable kinetics and high binding levels to brain regions with a plausible pattern for NFT deposition in AD subjects. In comparison, negligible tracer binding was observed in HE subjects. This pilot study suggests that simplified ratio methods such as SUVR can be used to quantify NFT binding. These results support further clinical development of 18F-MK-6240 for potential application in longitudinal studies.
Collapse
Affiliation(s)
- Talakad G Lohith
- Translational Biomarkers, Merck & Co., Inc., West Point, Pennsylvania
| | - Idriss Bennacef
- Translational Biomarkers, Merck & Co., Inc., West Point, Pennsylvania
| | - Rik Vandenberghe
- Neurology Department, University Hospitals Leuven, Leuven, Belgium; Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium; Alzheimer Research Centre, KU Leuven, Leuven Institute for Neuroscience and Disease, Leuven, Belgium
| | - Mathieu Vandenbulcke
- Neurology Department, University Hospitals Leuven, Leuven, Belgium; Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium; Alzheimer Research Centre, KU Leuven, Leuven Institute for Neuroscience and Disease, Leuven, Belgium
| | | | - Ruben Declercq
- Translational Pharmacology Europe, Merck Sharp & Dohme Corp., Brussels, Belgium
| | - Tom Reynders
- Translational Pharmacology Europe, Merck Sharp & Dohme Corp., Brussels, Belgium
| | | | - Kerry Riffel
- Translational Biomarkers, Merck & Co., Inc., West Point, Pennsylvania
| | - Sofie Celen
- Radiopharmaceutical Research, KU Leuven, Leuven, Belgium
| | - Kim Serdons
- Division of Nuclear Medicine, University Hospitals Leuven and UZ Leuven, Leuven, Belgium
| | - Guy Bormans
- Radiopharmaceutical Research, KU Leuven, Leuven, Belgium
| | - Kuenhi Tsai
- Early Clinical Statistics, Merck & Co., Inc., West Point, Pennsylvania
| | - Abbas Walji
- Discovery Chemistry, Merck & Co., Inc., West Point, Pennsylvania; and
| | - Eric D Hostetler
- Translational Biomarkers, Merck & Co., Inc., West Point, Pennsylvania
| | | | - Koen Van Laere
- Division of Nuclear Medicine, University Hospitals Leuven and UZ Leuven, Leuven, Belgium
| | - Mark Forman
- Translational Pharmacology, Merck & Co., Inc., North Wales, Pennsylvania
| | - Aubrey Stoch
- Translational Pharmacology, Merck & Co., Inc., North Wales, Pennsylvania
| | - Cyrille Sur
- Translational Biomarkers, Merck & Co., Inc., West Point, Pennsylvania
| | - Arie Struyk
- Translational Pharmacology, Merck & Co., Inc., North Wales, Pennsylvania
| |
Collapse
|
16
|
Bennacef I, Lohith T, Declercq R, Tom R, Telan‐Choing F, Celen S, Serdons K, Bormans G, Vandenbulcke M, Hoon J, Koole M, Laere K, Vandenberghe R, Sur C, Struyk A. [IC‐P‐177]: FIRST EVALUATION OF THE NEUROFIBRILLARY TANGLES RADIOLIGAND [
18
F]MK‐6240 IN ALZHEIMER's DISEASE PATIENTS. Alzheimers Dement 2017. [DOI: 10.1016/j.jalz.2017.06.2552] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
| | - Talakad Lohith
- Merck & Co.Inc., Translational Biomarkers, West PointPAUSA
| | - Ruben Declercq
- Merck Sharp & Dohme Inc., Translational Pharmacology EuropeBrusselsBelgium
| | - Reynders Tom
- Merck Sharp & Dohme Inc., Translational Pharmacology EuropeBrusselsBelgium
| | | | | | | | | | | | | | | | | | | | - Cyrille Sur
- Merck & Co.Inc., Translational Biomarkers, West PointPAUSA
| | - Arie Struyk
- Merck & Co.Inc., Translational PharmacologyNorth WalesPAUSA
| |
Collapse
|
17
|
Collier TL, Yokell DL, Livni E, Rice PA, Celen S, Serdons K, Neelamegam R, Bormans G, Harris D, Walji A, Hostetler ED, Bennacef I, Vasdev N. cGMP production of the radiopharmaceutical [ 18 F]MK-6240 for PET imaging of human neurofibrillary tangles. J Labelled Comp Radiopharm 2017; 60:263-269. [PMID: 28185305 DOI: 10.1002/jlcr.3496] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2016] [Revised: 02/03/2017] [Accepted: 02/06/2017] [Indexed: 01/15/2023]
Abstract
Fluorine-18-labelled 6-(fluoro)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine ([18 F]MK-6240) is a novel potent and selective positron emission tomography (PET) radiopharmaceutical for detecting human neurofibrillary tangles, which are made up of aggregated tau protein. Herein, we report the fully automated 2-step radiosynthesis of [18 F]MK-6240 using a commercially available radiosynthesis module, GE Healthcare TRACERlab FXFN . Nucleophilic fluorination of the 5-diBoc-6-nitro precursor with potassium cryptand [18 F]fluoride (K[18 F]/K222 ) was performed by conventional heating, followed by acid deprotection and semipreparative high-performance liquid chromatography under isocratic conditions. The isolated product was diluted with formulation solution and sterile filtered under Current Good Manufacturing Practices, and quality control procedures were established to validate this radiopharmaceutical for human use. At the end of synthesis, 6.3 to 9.3 GBq (170-250 mCi) of [18 F]MK-6240 was formulated and ready for injection, in an uncorrected radiochemical yield of 7.5% ± 1.9% (relative to starting [18 F]fluoride) with a specific activity of 222 ± 67 GBq/μmol (6.0 ± 1.8 Ci/μmol) at the end of synthesis (90 minutes; n = 3). [18 F]MK-6240 was successfully validated for human PET studies meeting all Food and Drug Administration and United States Pharmacopeia requirements for a PET radiopharmaceutical. The present method can be easily adopted for use with other radiofluorination modules for widespread clinical research use.
Collapse
Affiliation(s)
- Thomas Lee Collier
- Division of Nuclear Medicine and Molecular Imaging, Gordon Center for Medical Imaging, Massachusetts General Hospital, Boston, MA, USA.,Department of Radiology, Harvard Medical School, Boston, MA, USA.,Advion Inc., Ithaca, NY, USA
| | - Daniel L Yokell
- Division of Nuclear Medicine and Molecular Imaging, Gordon Center for Medical Imaging, Massachusetts General Hospital, Boston, MA, USA.,Department of Radiology, Harvard Medical School, Boston, MA, USA
| | - Eli Livni
- Division of Nuclear Medicine and Molecular Imaging, Gordon Center for Medical Imaging, Massachusetts General Hospital, Boston, MA, USA.,Department of Radiology, Harvard Medical School, Boston, MA, USA
| | - Peter A Rice
- Division of Nuclear Medicine and Molecular Imaging, Gordon Center for Medical Imaging, Massachusetts General Hospital, Boston, MA, USA
| | - Sofie Celen
- Laboratory for Radiopharmacy, Department of Pharmaceutical and Pharmacological Sciences, Campus Gasthuisberg O&N 2, KU Leuven, Leuven, Belgium
| | - Kim Serdons
- Department of Nuclear Medicine, UZ Leuven, Leuven, Belgium
| | - Ramesh Neelamegam
- Division of Nuclear Medicine and Molecular Imaging, Gordon Center for Medical Imaging, Massachusetts General Hospital, Boston, MA, USA.,Department of Radiology, Harvard Medical School, Boston, MA, USA
| | - Guy Bormans
- Laboratory for Radiopharmacy, Department of Pharmaceutical and Pharmacological Sciences, Campus Gasthuisberg O&N 2, KU Leuven, Leuven, Belgium
| | - Dawn Harris
- Merck Research Laboratories, Merck & Co., West Point, PA, USA
| | - Abbas Walji
- Merck Research Laboratories, Merck & Co., West Point, PA, USA
| | | | - Idriss Bennacef
- Merck Research Laboratories, Merck & Co., West Point, PA, USA
| | - Neil Vasdev
- Division of Nuclear Medicine and Molecular Imaging, Gordon Center for Medical Imaging, Massachusetts General Hospital, Boston, MA, USA.,Department of Radiology, Harvard Medical School, Boston, MA, USA
| |
Collapse
|
18
|
Bennacef I, Zeng Z, Lohith T, Miller PJ, Salinas CA, Connolly BM, Gantert LT, Hyking HD, Holahan MA, O’Malley SS, Purcell ML, Riffel K, Coleman PJ, Li J, Balsells-Padros J, Soriano A, Ogawa AM, Xu S, Xiaoping Z, Della Rocca J, Schachter JB, Hesk D, Telan-Choing F, Struyk A, Sur C, Celen S, Serdons K, Bormans G, Vandenbulcke M, Vandenberghe R, De Hoon J, Koole M, Van Laere K, Declercq R, Reynders T, Abbas W, Hostetler ED, Evelhoch J. IC‐P‐187: Discovery and First‐in‐Human Evaluation of the TAU‐imaging PET Radiotracer [
18
F]MK‐6240. Alzheimers Dement 2016. [DOI: 10.1016/j.jalz.2016.06.218] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
| | - Zhizhen Zeng
- Merck & Co. /Translational BiomarkersWest PointPA USA
| | | | | | | | | | | | | | | | | | | | - Kerry Riffel
- Merck & Co. /Translational BiomarkersWest PointPA USA
| | | | - Jing Li
- Merck & Co. /ChemistryWest PointPA USA
| | | | | | | | - Serena Xu
- Merck & Co. /PharmacologyKenilworthNJ USA
| | | | | | | | | | | | - Arie Struyk
- Merck & Co. /Translational PharmacologyNorth WalesPA USA
| | - Cyrille Sur
- Merck & Co. /Translational BiomarkersWest PointPA USA
| | | | | | | | | | | | | | | | - Koen Van Laere
- Nuclear Medicine and Molecular Imaging, KU LeuvenLeuvenBelgium
| | - Ruben Declercq
- Merck Sharp & Dohme Inc. /Translational Pharmacology EuropeBrusselsBelgium
| | | | | | | | | |
Collapse
|
19
|
Bennacef I, Zeng Z, Lohith T, Miller PJ, Salinas CA, Connolly BM, Gantert LT, Haley HD, Marie HA, O’Malley SS, Purcell ML, Riffel K, Coleman PJ, Li J, Balsells-Padros J, Soriano A, Ogawa AM, Xu S, Xiaoping Z, Della Rocca J, Schachter JB, Hesk D, David SJ, Telan-Choing F, Struyk A, Sur C, Celen S, Serdons K, Bormans G, Vandenbulcke M, Vandenberghe R, De Hoon J, Koole M, Van Laere K, Declercq R, Tom R, Abbas W, Eric HD, Evelhoch J. P1‐246: Discovery and First‐in‐Human Evaluation of the TAU‐Imaging PET Radiotracer [
18
F]MK‐6240. Alzheimers Dement 2016. [DOI: 10.1016/j.jalz.2016.06.995] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
| | - Zhizhen Zeng
- Merck & Co. / Translational BiomarkersWest PointPA USA
| | | | | | | | | | | | | | | | | | | | - Kerry Riffel
- Merck & Co. / Translational BiomarkersWest PointPA USA
| | | | - Jing Li
- Merck & Co. / ChemistryWest PointPA USA
| | | | | | | | - Serena Xu
- Merck & Co. / PharmacologyKenilworthNJ USA
| | | | | | | | | | | | | | - Arie Struyk
- Merck & Co. / Translational PharmacologyNorth WalesPA USA
| | - Cyrille Sur
- Merck & Co. / Translational BiomarkersWest PointPA USA
| | | | | | | | | | | | | | | | - Koen Van Laere
- Nuclear Medicine and Molecular Imaging, KU LeuvenLeuvenBelgium
| | - Ruben Declercq
- Merck Sharp & Dohme Inc. / Translational Pharmacology EuropeBrusselsBelgium
| | - Reynders Tom
- Merck Sharp & Dohme Inc. / Translational Pharmacology EuropeBrusselsBelgium
| | | | | | | |
Collapse
|
20
|
Ory D, Van den Brande J, de Groot T, Serdons K, Bex M, Declercq L, Cleeren F, Ooms M, Van Laere K, Verbruggen A, Bormans G. Retention of [18F]fluoride on reversed phase HPLC columns. J Pharm Biomed Anal 2015; 111:209-14. [DOI: 10.1016/j.jpba.2015.04.009] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2015] [Revised: 04/01/2015] [Accepted: 04/03/2015] [Indexed: 10/23/2022]
|
21
|
Ahmad R, Koole M, Evens N, Serdons K, Verbruggen A, Bormans G, Van Laere K. Whole-body biodistribution and radiation dosimetry of the cannabinoid type 2 receptor ligand [11C]-NE40 in healthy subjects. Mol Imaging Biol 2014; 15:384-90. [PMID: 23508466 DOI: 10.1007/s11307-013-0626-y] [Citation(s) in RCA: 59] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
PURPOSE The type 2 cannabinoid receptor (CB2R) is part of the human endocannabinoid system and is involved in central and peripheral inflammatory processes. In vivo imaging of the CB2R would allow study of several (neuro)inflammatory disorders. In this study we have investigated the safety and tolerability of [11C]-NE40, a CB2R positron emission tomography (PET) ligand, in healthy human male subjects and determined its biodistribution and radiation dosimetry. PROCEDURE Six healthy male subjects (age 20-65 years) underwent a dynamic series of nine whole-body PET/CT scans for up to 140 min, after injection of an average bolus of 286 MBq of [11C]-NE40. Organ absorbed and total effective doses were calculated through OLINDA. RESULTS [11C]-NE40 showed high initial uptake in the spleen and a predominant hepatobiliary excretion. In the brain, rapid uptake and swift washout were seen. Organ absorbed doses were largest for the small intestine and liver, with 15.6 and 11.5 μGy/MBq, respectively. The mean effective dose was 3.64±0.81 μSv/MBq. There were no changes with aging observed. No adverse events were encountered. CONCLUSIONS This first-in-man study of [11C]-NE40 showed an expected biodistribution compatible with lymphoid tissue uptake and appropriate fast brain kinetics in the healthy human brain, underscoring the potential of this tracer for further application in central and peripheral inflammation imaging. The effective dose is within the typical expected range for 11C ligands.
Collapse
Affiliation(s)
- Rawaha Ahmad
- Division of Nuclear Medicine, University Hospital Leuven, Herestraat 49, 3000, Leuven, Belgium.
| | | | | | | | | | | | | |
Collapse
|
22
|
Vermeersch SGG, de Hoon J, De Saint-Hubert B, Derdelinckx I, Serdons K, Bormans G, Reynders T, Declercq R, De Lepeleire I, Kennedy W, Blanchard R, Marcantonio E, Hargreaves R, Li CC, Sanabria S, Hostetler E, Joshi A, Evelhoch J, Van Laere K. PET imaging in healthy subjects and migraineurs suggests CGRP receptor antagonists do not have to act centrally to achieve clinical efficacy. J Headache Pain 2013. [DOI: 10.1186/1129-2377-14-s1-p224] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
23
|
Vermeersch SGG, de Hoon J, De Saint-Hubert B, Derdelinckx I, Serdons K, Bormans G, Reynders T, Declercq R, De Lepeleire I, Kennedy W, Blanchard R, Marcantonio E, Hargreaves R, Li CC, Sanabria S, Hostetler E, Joshi A, Evelhoch J, Van Laere K. PET imaging in healthy subjects and migraineurs suggests CGRP receptor antagonists do not have to act centrally to achieve clinical efficacy. J Headache Pain 2013. [PMCID: PMC3620296 DOI: 10.1186/1129-2377-1-s14-p224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Affiliation(s)
- SGG Vermeersch
- Center for Clinical Pharmacology, Campus Gasthuisberg, University Hospitals Leuven (KU Leuven), Leuv, Belgium
| | - J de Hoon
- Center for Clinical Pharmacology, Campus Gasthuisberg, University Hospitals Leuven (KU Leuven), Leuv, Belgium
| | - B De Saint-Hubert
- Center for Clinical Pharmacology, Campus Gasthuisberg, University Hospitals Leuven (KU Leuven), Leuv, Belgium
| | - I Derdelinckx
- Center for Clinical Pharmacology, Campus Gasthuisberg, University Hospitals Leuven (KU Leuven), Leuv, Belgium
| | - K Serdons
- Nuclear Medicine Department, UZ and KU Leuven, Belgium
| | - G Bormans
- Laboratory for Radiopharmacy, KU Leuven, Belgium
| | - T Reynders
- Merck Sharp & Dohme (Europe) Inc., Brussels, Belgium
| | - R Declercq
- Merck Sharp & Dohme (Europe) Inc., Brussels, Belgium
| | | | - W Kennedy
- Merck Research Laboratories, Upper Gwynedd PA, USA
| | - R Blanchard
- Merck Research Laboratories, Upper Gwynedd PA, USA
| | | | | | - CC Li
- Merck Research Laboratories, West Point PA, USA
| | - S Sanabria
- Merck Research Laboratories, West Point PA, USA
| | - E Hostetler
- Merck Research Laboratories, West Point PA, USA
| | - A Joshi
- Merck Research Laboratories, West Point PA, USA
| | - J Evelhoch
- Merck Research Laboratories, West Point PA, USA
| | - K Van Laere
- Nuclear Medicine Department, UZ and KU Leuven, Belgium
| |
Collapse
|
24
|
Vermeersch SGG, de Hoon J, De Saint-Hubert B, Derdelinckx I, Serdons K, Bormans G, Reynders T, Declercq R, De Lepeleire I, Kennedy W, Blanchard R, Marcantonio E, Hargreaves R, Li CC, Sanabria S, Hostetler E, Joshi A, Evelhoch J, Van Laere K. PET imaging in healthy subjects and migraineurs suggests CGRP receptor antagonists do not have to act centrally to achieve clinical efficacy. J Headache Pain 2013. [DOI: 10.1186/1129-2377-1-s1-p224] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
25
|
Sanabria-Bohorquez S, Van Laere K, Koole M, Bormans G, Serdons K, Hoon J, Vandenberghe R, De Lepeleire I, Reynders T, Zeng Z, Williams D, Rosen L, Hargreaves R, Sur C, Forman M, Hostetler E. P3‐179: Development of the amyloid PET radioligand [
18
F]MK‐3328. Alzheimers Dement 2010. [DOI: 10.1016/j.jalz.2010.05.1677] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
| | - Koen Van Laere
- Division of Nuclear Medicine University Hospital LeuvenLeuven Belgium
| | - Michel Koole
- Division of Nuclear Medicine University Hospital LeuvenLeuven Belgium
| | - Guy Bormans
- Laboratory for RadiopharmacyK.U. Leuven Leuven Belgium
| | - Kim Serdons
- Laboratory for RadiopharmacyK.U. Leuven Leuven Belgium
| | - Jan Hoon
- Center for Clinical Pharmacology University Hospital LeuvenLeuven Belgium
| | - Rik Vandenberghe
- Department of Neurology University Hospital LeuvenLeuven Belgium
| | | | - Tom Reynders
- Clinical Pharmacology, Merck Sharp & DohmeBrussels Belgium
| | | | | | - Laura Rosen
- Clinical Pharmacology, MerckWest Point PA USA
| | | | | | - Mark Forman
- Clinical Pharmacology, MerckWest Point PA USA
| | | |
Collapse
|
26
|
Serdons K, Van Laere K, Janssen P, Kung HF, Bormans G, Verbruggen A. Synthesis and Evaluation of Three 18F-Labeled Aminophenylbenzothiazoles as Amyloid Imaging Agents. J Med Chem 2009; 52:7090-102. [DOI: 10.1021/jm900871v] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Kim Serdons
- Laboratory for Radiopharmacy, Katholieke Universiteit Leuven, Leuven, Belgium
| | - Koen Van Laere
- Department of Nuclear Medicine, U.Z. Gasthuisberg, Leuven, Belgium
| | - Peter Janssen
- Department of Neurophysiology, Katholieke Universiteit Leuven, Leuven, Belgium
| | - Hank F. Kung
- Department of Radiology, University of Pennsylvania, Pennsylvania
| | - Guy Bormans
- Laboratory for Radiopharmacy, Katholieke Universiteit Leuven, Leuven, Belgium
| | - Alfons Verbruggen
- Laboratory for Radiopharmacy, Katholieke Universiteit Leuven, Leuven, Belgium
| |
Collapse
|
27
|
Serdons K, Vanderghinste D, Van Eeckhoudt M, Borghgraef P, Kung H, Van Leuven F, de Groot T, Bormans G, Verbruggen A. Synthesis and evaluation of two fluorine-18 labelled phenylbenzothiazoles as potentialin vivotracers for amyloid plaque imaging. J Labelled Comp Radiopharm 2009. [DOI: 10.1002/jlcr.1662] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
28
|
Serdons K, Vanderghinste D, Van Eeckhoudt M, Cleynhens J, de Groot T, Bormans G, Verbruggen A. Synthesis and evaluation of two uncharged99mTc-labeled derivatives of thioflavin-T as potential tracer agents for fibrillar brain amyloid. J Labelled Comp Radiopharm 2009. [DOI: 10.1002/jlcr.1592] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
29
|
Serdons K, Verduyckt T, Vanderghinste D, Borghgraef P, Cleynhens J, Van Leuven F, Kung H, Bormans G, Verbruggen A. 11C-labelled PIB analogues as potential tracer agents for in vivo imaging of amyloid β in Alzheimer's disease. Eur J Med Chem 2009; 44:1415-26. [DOI: 10.1016/j.ejmech.2008.09.038] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2008] [Revised: 09/18/2008] [Accepted: 09/18/2008] [Indexed: 10/21/2022]
|
30
|
Abstract
Positron emission tomography (PET) is a fully translational molecular imaging technique that requires specific probes radiolabelled with short-lived positron emitting radionuclides. This review discusses relevant methods which are applied throughout the different steps in the development of new PET probes for in vivo visualization of specific molecular targets related to diagnosis or important for drug development.
Collapse
Affiliation(s)
- Kim Serdons
- Laboratory for Radiopharmacy, K.U.Leuven, Herestraat 49 bus 821, BE3000 Leuven, Belgium
| | | | | |
Collapse
|
31
|
Serdons K, Terwinghe C, Vermaelen P, Van Laere K, Kung H, Mortelmans L, Bormans G, Verbruggen A. Synthesis and Evaluation of 18F-Labeled 2-Phenylbenzothiazoles as Positron Emission Tomography Imaging Agents for Amyloid Plaques in Alzheimer’s Disease. J Med Chem 2009; 52:1428-37. [DOI: 10.1021/jm8013376] [Citation(s) in RCA: 75] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Kim Serdons
- Laboratory for Radiopharmacy, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven, Leuven, Belgium, Department of Nuclear Medicine, U. Z. Gasthuisberg, Leuven, Belgium, and Department of Radiology, University of Pennsylvania, Philadelphia
| | - Christelle Terwinghe
- Laboratory for Radiopharmacy, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven, Leuven, Belgium, Department of Nuclear Medicine, U. Z. Gasthuisberg, Leuven, Belgium, and Department of Radiology, University of Pennsylvania, Philadelphia
| | - Peter Vermaelen
- Laboratory for Radiopharmacy, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven, Leuven, Belgium, Department of Nuclear Medicine, U. Z. Gasthuisberg, Leuven, Belgium, and Department of Radiology, University of Pennsylvania, Philadelphia
| | - Koen Van Laere
- Laboratory for Radiopharmacy, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven, Leuven, Belgium, Department of Nuclear Medicine, U. Z. Gasthuisberg, Leuven, Belgium, and Department of Radiology, University of Pennsylvania, Philadelphia
| | - Hank Kung
- Laboratory for Radiopharmacy, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven, Leuven, Belgium, Department of Nuclear Medicine, U. Z. Gasthuisberg, Leuven, Belgium, and Department of Radiology, University of Pennsylvania, Philadelphia
| | - Luc Mortelmans
- Laboratory for Radiopharmacy, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven, Leuven, Belgium, Department of Nuclear Medicine, U. Z. Gasthuisberg, Leuven, Belgium, and Department of Radiology, University of Pennsylvania, Philadelphia
| | - Guy Bormans
- Laboratory for Radiopharmacy, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven, Leuven, Belgium, Department of Nuclear Medicine, U. Z. Gasthuisberg, Leuven, Belgium, and Department of Radiology, University of Pennsylvania, Philadelphia
| | - Alfons Verbruggen
- Laboratory for Radiopharmacy, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven, Leuven, Belgium, Department of Nuclear Medicine, U. Z. Gasthuisberg, Leuven, Belgium, and Department of Radiology, University of Pennsylvania, Philadelphia
| |
Collapse
|
32
|
Serdons K, Verduyckt T, Vanderghinste D, Cleynhens J, Borghgraef P, Vermaelen P, Terwinghe C, Van Leuven F, Van Laere K, Kung H, Bormans G, Verbruggen A. Synthesis of 18F-labelled 2-(4'-fluorophenyl)-1,3-benzothiazole and evaluation as amyloid imaging agent in comparison with [11C]PIB. Bioorg Med Chem Lett 2008; 19:602-5. [PMID: 19147351 DOI: 10.1016/j.bmcl.2008.12.069] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2008] [Revised: 12/16/2008] [Accepted: 12/16/2008] [Indexed: 10/21/2022]
Abstract
2-(4'-[(18)F]fluorophenyl)-1,3-benzothiazole was synthesized as a fluorine-18 labelled derivative of the Pittsburg Compound-B (PIB), which has known affinity for amyloid beta and promising characteristics as tracer for in vivo visualisation of amyloid deposits in patients suffering from Alzheimer's disease (AD). Both the nitro-precursor 2-(4'-nitrophenyl)-1,3-benzothiazole and the non-radioactive reference compound were synthesized using a 1-step synthesis pathway. Labelling was achieved by direct aromatic nucleophilic substitution of the nitro-precursor using [(18)F]fluoride by heating for 20 min at 150 degrees C and with a radiochemical yield of 38%. The reference compound showed high affinity for amyloid in an in vitro competition binding study using human AD brain homogenates (K(i)=9.0 nM) and fluorescence imaging of incubated transgenic APP mouse brain slices confirmed binding to amyloid plaques. A biodistribution study in normal mice showed a high brain uptake at 2 min pi (3.20%ID/g) followed by a fast washout (60 min pi: 0.21%ID/g). A dynamic microPET study was performed in a transgenic APP and normal WT mouse, but, similar to [(11)C]PIB, no difference was seen in tracer retention between both kind of mice. The new (18)F-labelled 2-phenylbenzothiazole showed excellent preclinical characteristics comparable with those of the (11)C-labelled PIB.
Collapse
Affiliation(s)
- K Serdons
- Laboratory for Radiopharmacy, K.U.Leuven, Herestraat 49-bus 821, B-3000 Leuven, Belgium.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
|
34
|
Serdons K, Verduyckt T, Cleynhens J, Bormans G, Verbruggen A. Development of99mTc-thioflavin-T derivatives for detection of systemic amyloidosis. J Labelled Comp Radiopharm 2008. [DOI: 10.1002/jlcr.1536] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
35
|
Serdons K, Verduyckt T, Cleynhens J, Terwinghe C, Mortelmans L, Bormans G, Verbruggen A. Synthesis and evaluation of a 99mTc-BAT-phenylbenzothiazole conjugate as a potential in vivo tracer for visualization of amyloid β. Bioorg Med Chem Lett 2007; 17:6086-90. [PMID: 17904367 DOI: 10.1016/j.bmcl.2007.09.055] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2007] [Revised: 09/13/2007] [Accepted: 09/13/2007] [Indexed: 10/22/2022]
Abstract
We have conjugated S,S'-bis-trityl-N-BOC-N'-acetic acid-1,2-ethylenedicysteamine, a protected bis-amino-bis-thiol (BAT) tetraligand, with 2-(4'-aminophenyl)-1,3-benzothiazole, a derivative of thioflavin-T with known affinity for amyloid. The conjugate was efficiently labelled with (99m)Tc by heating of the protected precursor in diluted hydrochloric acid followed by neutralization and heating in the presence of (99m)Tc-tartrate. It was demonstrated that the (99m)Tc-BAT-phenylbenzothiazole conjugate binds in vitro to amyloid beta present in postmortem brain slices of Alzheimer's patients. Despite its high lipophilicity and neutral character, the radiolabelled conjugate did not cross the blood-brain barrier to a sufficient degree and therefore is not useful for detection of Alzheimer's disease. Further evaluation of this (99m)Tc-labelled tracer agent could elucidate its potential usefulness to visualize amyloid plaques in peripheral amyloidosis.
Collapse
Affiliation(s)
- K Serdons
- Laboratory for Radiopharmacy, K.U. Leuven, Leuven, Belgium.
| | | | | | | | | | | | | |
Collapse
|